341 related articles for article (PubMed ID: 33976188)
21. [Dihydromyricetin reverses Herceptin resistance by up-regulating miR-98-5p and inhibiting IGF1R/HER2 dimer formation in SKBR3 cells].
Zhang M; Guo C; Chu Y; Xu R; Yin F; Qian J
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Feb; 42(2):207-214. PubMed ID: 35365444
[TBL] [Abstract][Full Text] [Related]
22. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.
Camirand A; Lu Y; Pollak M
Med Sci Monit; 2002 Dec; 8(12):BR521-6. PubMed ID: 12503030
[TBL] [Abstract][Full Text] [Related]
23. Cullin7 enhances resistance to trastuzumab therapy in Her2 positive breast cancer via degrading IRS-1 and downregulating IGFBP-3 to activate the PI3K/AKT pathway.
Qiu N; He YF; Zhang SM; Zhan YT; Han GD; Jiang M; He WX; Zhou J; Liang HL; Ao X; Xia HM; Li J; Yang YY; He ZM; Zou ZZ; Li HS
Cancer Lett; 2019 Nov; 464():25-36. PubMed ID: 31461670
[TBL] [Abstract][Full Text] [Related]
24. t-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells.
Lenz G; Hamilton A; Geng S; Hong T; Kalkum M; Momand J; Kane SE; Huss JM
Clin Cancer Res; 2018 Mar; 24(5):1216-1226. PubMed ID: 29180608
[No Abstract] [Full Text] [Related]
25. Dynamic microRNA activity identifies therapeutic targets in trastuzumab-resistant HER2
Decker JT; Hall MS; Blaisdell RB; Schwark K; Jeruss JS; Shea LD
Biotechnol Bioeng; 2018 Oct; 115(10):2613-2623. PubMed ID: 29981261
[TBL] [Abstract][Full Text] [Related]
26. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).
Lu Y; Zi X; Zhao Y; Mascarenhas D; Pollak M
J Natl Cancer Inst; 2001 Dec; 93(24):1852-7. PubMed ID: 11752009
[TBL] [Abstract][Full Text] [Related]
27. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
[TBL] [Abstract][Full Text] [Related]
28. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
Liu B; Fan Z; Edgerton SM; Yang X; Lind SE; Thor AD
Cell Cycle; 2011 Sep; 10(17):2959-66. PubMed ID: 21862872
[TBL] [Abstract][Full Text] [Related]
29. Age-related differences in insulin-like growth factor-1 receptor signaling regulates Akt/FOXO3a and ERK/Fos pathways in vascular smooth muscle cells.
Li M; Chiu JF; Gagne J; Fukagawa NK
J Cell Physiol; 2008 Nov; 217(2):377-87. PubMed ID: 18615585
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic destruction of insulin receptor substrates for cancer treatment.
Reuveni H; Flashner-Abramson E; Steiner L; Makedonski K; Song R; Shir A; Herlyn M; Bar-Eli M; Levitzki A
Cancer Res; 2013 Jul; 73(14):4383-94. PubMed ID: 23651636
[TBL] [Abstract][Full Text] [Related]
31. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus.
Kalinina T; Bockhorn M; Kaifi JT; Thieltges S; Güngör C; Effenberger KE; Strelow A; Reichelt U; Sauter G; Pantel K; Izbicki JR; Yekebas EF
Int J Cancer; 2010 Oct; 127(8):1931-40. PubMed ID: 20104520
[TBL] [Abstract][Full Text] [Related]
32. Identification of a Novel Invasion-Promoting Region in Insulin Receptor Substrate 2.
Mercado-Matos J; Janusis J; Zhu S; Chen SS; Shaw LM
Mol Cell Biol; 2018 Jul; 38(14):. PubMed ID: 29685905
[TBL] [Abstract][Full Text] [Related]
33. Insulin Receptor Substrate 1, the Hub Linking Follicle-stimulating Hormone to Phosphatidylinositol 3-Kinase Activation.
Law NC; Hunzicker-Dunn ME
J Biol Chem; 2016 Feb; 291(9):4547-60. PubMed ID: 26702053
[TBL] [Abstract][Full Text] [Related]
34. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
Gardaneh M; Shojaei S; Kaviani A; Behnam B
Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540
[TBL] [Abstract][Full Text] [Related]
35. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
Zhao Y; Wang Z; Jiang Y; Yang C
Cancer Lett; 2011 Dec; 313(1):54-63. PubMed ID: 21943825
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
37. Type 1 Insulin-Like Growth Factor Receptor/Insulin Receptor Substrate 1 Signaling Confers Pathogenic Activity on Breast Tumor Cells Lacking REST.
Meyer K; Albaugh B; Schoenike B; Roopra A
Mol Cell Biol; 2015 Sep; 35(17):2991-3004. PubMed ID: 26100015
[TBL] [Abstract][Full Text] [Related]
38. Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells.
Yan F; Liao R; Farhan M; Wang T; Chen J; Wang Z; Little PJ; Zheng W
Biomed Pharmacother; 2016 Dec; 84():1538-1550. PubMed ID: 27881235
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis.
Liu H; Song Y; Qiu H; Liu Y; Luo K; Yi Y; Jiang G; Lu M; Zhang Z; Yin J; Zeng S; Chen X; Deng M; Jia X; Gu Y; Chen D; Zheng G; He Z
Cell Death Differ; 2020 Mar; 27(3):966-983. PubMed ID: 31296961
[TBL] [Abstract][Full Text] [Related]
40. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
